Trial · NCT02831764
Participant flow50
How many started, completed or left each group, period by period.
1 to 20 of 50
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Phase (Day1 to Week 96) | STARTED | DTG + 3TC - Double-blind Phase | 360 | |
| Double-blind Phase (Day1 to Week 96) | STARTED | DTG + TDF/FTC - Double-blind Phase | 362 | |
| Double-blind Phase (Day1 to Week 96) | STARTED | DTG + 3TC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | STARTED | DTG + TDF/FTC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | STARTED | DTG + 3TC - Continuation Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | Intent-to-Treat Exposed | DTG + 3TC - Double-blind Phase | 360 | |
| Double-blind Phase (Day1 to Week 96) | Intent-to-Treat Exposed | DTG + TDF/FTC - Double-blind Phase | 359 | |
| Double-blind Phase (Day1 to Week 96) | Intent-to-Treat Exposed | DTG + 3TC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | Intent-to-Treat Exposed | DTG + TDF/FTC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | Intent-to-Treat Exposed | DTG + 3TC - Continuation Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | COMPLETED | DTG + 3TC - Double-blind Phase | 319 | |
| Double-blind Phase (Day1 to Week 96) | COMPLETED | DTG + TDF/FTC - Double-blind Phase | 327 | |
| Double-blind Phase (Day1 to Week 96) | COMPLETED | DTG + 3TC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | COMPLETED | DTG + TDF/FTC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | COMPLETED | DTG + 3TC - Continuation Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | NOT COMPLETED | DTG + 3TC - Double-blind Phase | 41 | |
| Double-blind Phase (Day1 to Week 96) | NOT COMPLETED | DTG + TDF/FTC - Double-blind Phase | 35 | |
| Double-blind Phase (Day1 to Week 96) | NOT COMPLETED | DTG + 3TC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | NOT COMPLETED | DTG + TDF/FTC - Open-label Phase | 0 | |
| Double-blind Phase (Day1 to Week 96) | NOT COMPLETED | DTG + 3TC - Continuation Phase | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02831764/flow